<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817855</url>
  </required_header>
  <id_info>
    <org_study_id>D2550C00002</org_study_id>
    <nct_id>NCT01817855</nct_id>
  </id_info>
  <brief_title>To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients</brief_title>
  <official_title>A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics
      of multiple ascending doses of AZD7624 in healthy subjects and patients with chronic
      obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety,
      Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to
      Healthy Subjects and Patients with COPD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 24 days</time_frame>
    <description>Summary of number of subjects who had at least one adverse event in any category (Safety analysis set)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Pharmacokinetic Parameters (AUC(0-tau) )</measure>
    <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
    <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9.
*AUC(0-tau) = AUC(0-last) where for cohorts 2,3,4,5 and 6 tau=24 hours and for cohort 1, tau=12 hours .
Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Pharmacokinetic Parameters (Cmax)</measure>
    <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
    <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Pharmacokinetic Parameters (Cmin)</measure>
    <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
    <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>COPD</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.
COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7624</intervention_name>
    <description>Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match</intervention_name>
    <description>Multiple doses inhaled placebo via a nebulizer</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable
             veins for cannulation or repeated venipuncture.

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Plasma myoglobin and CK not above the upper reference range of the analysing
             laboratory at Day -1

          -  Male and/or female patients with COPD aged above18 years with suitable veins for
             cannulation or repeated venipuncture.

          -  Clinical diagnosis of COPD for more than 1 year at Visit 1, according to the Global
             Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines

        Exclusion Criteria:

          -  Any clinically important illness, medical/surgical procedure or trauma within 4 weeks
             of the first administration of the IP

          -  Receipt of another new chemical entity (defined as a compound which has not been
             approved for marketing) or participation in any other clinical study that included
             drug treatment within at least 3 months of the first administration of the IP in this
             study

          -  Any clinically important abnormalities in clinical chemistry, haematology or
             urinalysis results as judged by the Investigator

          -  Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV)

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saeed Khan, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drg Research Centre At Guys Hosipital, 6 Newcomen Street London SE1 1YR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naimish Patel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca, Wilmington, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1273&amp;filename=D2550C00002_synopsis.pdf</url>
    <description>CSR Synopsis</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>October 23, 2015</results_first_submitted>
  <results_first_submitted_qc>February 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 30, 2016</results_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1,</keyword>
  <keyword>Safety,</keyword>
  <keyword>Tolerability,</keyword>
  <keyword>Healthy,</keyword>
  <keyword>COPD patients</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Both the lung deposited doses and total delivered doses are reported in clinical study report, and the conversion is: In cohort 1 to 6, the lung deposited doses 151 µg, 303 µg, 595 µg, 1191 µg, 1160 µg and 580 µg are equivalent to the delivered doses 261µg, 522µg, 1027µg, 2053µg, 1932µg and 966µg, respectively.</recruitment_details>
      <pre_assignment_details>The screening period for all the subjects was from Day -42 to Day -2. Admission on day -1. A 8 to 9 days treatment period, 7 to 9 days follow up period. It was planned to enrol to 32 healthy volunteers and 20 COPD to the study, but 4 COPD patients (Due to stopping cohort 4 prematurly) and one healthy volunteer (in cohort 3) were not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD7624 Healthy Volunteers</title>
          <description>Healthy Volunteers with 261 µg to 2053 µg delivered dose of AZD7624, once daily or twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo Healthy Volunteers</title>
          <description>Healthy Volunteers with Placebo, once daily or twice daily</description>
        </group>
        <group group_id="P3">
          <title>AZD7624 COPD</title>
          <description>COPD patients with 966 µg or 1932 µg delivered dose of AZD7624, once daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo COPD</title>
          <description>COPD Patients with Placebo, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who received at least 1 dose of the investigational product, AZD7624 or placebo and for whom any postdose data were available were included in the analysis (safety population).</population>
      <group_list>
        <group group_id="B1">
          <title>AZD7624 Healthy Volunteers</title>
          <description>Healthy Volunteers with 261 µg to 2053 µg delivered dose of AZD7624, once daily or twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo Healthy Volunteers</title>
          <description>Healthy Volunteers with Placebo, once daily or twice daily</description>
        </group>
        <group group_id="B3">
          <title>AZD7624 COPD</title>
          <description>COPD patients with 966 µg or 1932 µg delivered dose of AZD7624, once daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo COPD</title>
          <description>COPD Patients with Placebo, once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="9.7"/>
                    <measurement group_id="B2" value="32" spread="9.1"/>
                    <measurement group_id="B3" value="65" spread="9.7"/>
                    <measurement group_id="B4" value="65" spread="8.7"/>
                    <measurement group_id="B5" value="45.3" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Summary of number of subjects who had at least one adverse event in any category (Safety analysis set)</description>
        <time_frame>Up to 24 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD7624 Healthy Volunteers</title>
            <description>Healthy Volunteers with 261 µg to 2053 µg delivered dose of AZD7624, once daily or twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo Healthy Volunteers</title>
            <description>Healthy Volunteers with Placebo, once daily or twice daily</description>
          </group>
          <group group_id="O3">
            <title>AZD7624 COPD</title>
            <description>COPD patients with 966 µg or 1932 µg delivered dose of AZD7624, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo COPD</title>
            <description>COPD Patients with Placebo, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Summary of number of subjects who had at least one adverse event in any category (Safety analysis set)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE with outcome = death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE (including events with outcome = death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Pharmacokinetic Parameters (AUC(0-tau) )</title>
        <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9.
*AUC(0-tau) = AUC(0-last) where for cohorts 2,3,4,5 and 6 tau=24 hours and for cohort 1, tau=12 hours .
Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
        <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7624 COPD Cohort 4</title>
            <description>COPD patients on Cohort 4 with 1932 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O2">
            <title>AZD7624 Healthy Volunteers Cohort 5</title>
            <description>Healthy volunteers on Cohort 5 with 2053 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O3">
            <title>AZD7624 COPD Cohort 6</title>
            <description>COPD patients on Cohort 6 with 966 µg delivered dose of AZD7624, once daily</description>
          </group>
          <group group_id="O4">
            <title>AZD7624 Healthy Volunteers Cohort 1</title>
            <description>Healthy volunteers on Cohort 1 with 261 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O5">
            <title>AZD7624 Healthy Volunteers Cohort 2</title>
            <description>Healthy volunteers on Cohort 2 with 522 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O6">
            <title>AZD7624 Healthy Volunteers Cohort 3</title>
            <description>Healthy volunteers on Cohort 3 with 1027 µg delivered dose of AZD7624, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pharmacokinetic Parameters (AUC(0-tau) )</title>
          <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9.
*AUC(0-tau) = AUC(0-last) where for cohorts 2,3,4,5 and 6 tau=24 hours and for cohort 1, tau=12 hours .
Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
          <population>PK analysis set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="11.4"/>
                    <measurement group_id="O2" value="27.4" spread="17.3"/>
                    <measurement group_id="O3" value="13.3" spread="50.4"/>
                    <measurement group_id="O4" value="3.88" spread="28.5"/>
                    <measurement group_id="O5" value="9.31" spread="12.7"/>
                    <measurement group_id="O6" value="15.2" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Pharmacokinetic Parameters (Cmax)</title>
        <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
        <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7624 COPD Cohort 4</title>
            <description>COPD patients on Cohort 4 with 1932 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O2">
            <title>AZD7624 Healthy Volunteers Cohort 5</title>
            <description>Healthy volunteers on Cohort 5 with 2053 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O3">
            <title>AZD7624 COPD Cohort 6</title>
            <description>COPD patients on Cohort 6 with 966 µg delivered dose of AZD7624, once daily</description>
          </group>
          <group group_id="O4">
            <title>AZD7624 Healthy Volunteers Cohort 1</title>
            <description>Healthy volunteers on Cohort 1 with 261 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O5">
            <title>AZD7624 Healthy Volunteers Cohort 2</title>
            <description>Healthy volunteers on Cohort 2 with 522 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O6">
            <title>AZD7624 Healthy Volunteers Cohort 3</title>
            <description>Healthy volunteers on Cohort 3 with 1027 µg delivered dose of AZD7624, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pharmacokinetic Parameters (Cmax)</title>
          <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
          <population>PK analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="13.4"/>
                    <measurement group_id="O2" value="15.6" spread="38.3"/>
                    <measurement group_id="O3" value="3.08" spread="54.6"/>
                    <measurement group_id="O4" value="2.14" spread="49.5"/>
                    <measurement group_id="O5" value="6.23" spread="22.8"/>
                    <measurement group_id="O6" value="8.07" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Pharmacokinetic Parameters (Cmin)</title>
        <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
        <time_frame>PK concentration was measured at 0, 15min, 30min, 45min, 1hr, 2hr, 4hr, 6hr, 9hr, 12hr, 18hr and 24hr post dose on Day 7 for cohort 6, Day 8 for cohorts 1,4 and 5 and on Day 9 for cohorts 2 and 3.</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>AZD7624 COPD Cohort 4</title>
            <description>COPD patients on Cohort 4 with 1932 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O2">
            <title>AZD7624 Healthy Volunteers Cohort 5</title>
            <description>Healthy volunteers on Cohort 5 with 2053 µg delivered dose of AZD7624 , once daily</description>
          </group>
          <group group_id="O3">
            <title>AZD7624 COPD Cohort 6</title>
            <description>COPD patients on Cohort 6 with 966 µg delivered dose of AZD7624, once daily</description>
          </group>
          <group group_id="O4">
            <title>AZD7624 Healthy Volunteers Cohort 1</title>
            <description>Healthy volunteers on Cohort 1 with 261 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O5">
            <title>AZD7624 Healthy Volunteers Cohort 2</title>
            <description>Healthy volunteers on Cohort 2 with 522 µg delivered dose of AZD7624, twice daily</description>
          </group>
          <group group_id="O6">
            <title>AZD7624 Healthy Volunteers Cohort 3</title>
            <description>Healthy volunteers on Cohort 3 with 1027 µg delivered dose of AZD7624, twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pharmacokinetic Parameters (Cmin)</title>
          <description>Summary of pharmacokinetic parameters of AZD7624 after multiple once daily dose administration in cohorts 4,5,6 and multiple twice daily administration in cohorts 1,2 and 3, on Days 7, 8 or 9. Results are presented for cohort 1,2,3,4,5 with SPIRA device and for cohort 6 with ADI device (test device).
Number of Participants Analyzed is based on the available data for the used device and for the day that PK measurements were taken.</description>
          <population>PK analysis set</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.797" spread="22.2"/>
                    <measurement group_id="O2" value="0.602" spread="15.7"/>
                    <measurement group_id="O3" value="0.355" spread="47.3"/>
                    <measurement group_id="O4" value="0.183" spread="44.0"/>
                    <measurement group_id="O5" value="0.453" spread="18.6"/>
                    <measurement group_id="O6" value="0.719" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD7624 Healthy Volunteers</title>
          <description>Healthy Volunteers with 261 µg to 2053 µg delivered dose of AZD7624, once daily or twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo Healthy Volunteers</title>
          <description>Healthy Volunteers with Placebo, once daily or twice daily</description>
        </group>
        <group group_id="E3">
          <title>AZD7624 COPD</title>
          <description>COPD patients with 966 µg or 1932 µg delivered dose of AZD7624, once daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo COPD</title>
          <description>COPD Patients with Placebo, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth ulceration, Dry mouth, Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort, Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis, Upper respiratory tract infection, Rhinitis, Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain, Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness, Headache, Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough, Bronchospasm, Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papule, Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naimish Patel</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+1 781 839 4061</phone>
      <email>Naimish.Patel@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

